breast cancer
Conditions
Interventions
Case series:None
Sponsors
Zhongshan Hospital Affiliated to Dalian University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Voluntary signed informed consent. Age = 18, gender not limited. ECOG performance status: 0 to 4. Good compliance and willingness to follow the study-related procedures, able to complete a questionnaire survey about their environmental/occupational exposure and smoking/drinking history. Patients with any subtype and stage of breast cancer (irrespective of estrogen receptor, progesterone receptor and HER2 receptor status). Available surgical tissue or sufficient biopsy tissue from the primary or metastatic site, able to obtain cultured tumor tissue samples. Life expectancy of at least 12 weeks. Normal function of major organs, including the heart, liver, kidneys and hematopoietic function of bone marrow.
Exclusion criteria
Exclusion criteria: Below 18 years old. Severe neurological or psychiatric disorders, including epilepsy, dementia, physical or mental incapacity to sign the informed consent, unable to provide informed consent (language, intelligence, etc.). Refused to participate. Unable to obtain biopsy and/or surgery, pleural fluid, ascites, pericardial fluid, and cerebrospinal fluid samples. Insufficient breast tissue for histological analysis or remaining breast tissue not sufficient for routine pathological analysis. Allergic to anti-tumor treatment drugs or have surgical contraindications and are unable to receive any anti-tumor treatment. Any other active malignant tumor history within the past 5 years before enrollment. According to the judgment of the attending physician, the patient will be unable to meet the requirements of the study. Severe liver disease, cardiovascular disease, kidney disease, respiratory disease, blood disease or uncontrolled diabetes. HIV patients. Pregnant and lactating patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organoid characteristics and drug sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biological biomarkers for the therapeutic effects, side effects, and prognosis of different anti-tumor drugs and treatment regimens; | — |
Countries
China
Contacts
Public ContactRuoyu Wang
Zhongshan Hospital Affiliated to Dalian University
Outcome results
None listed